Dashboard
Manage Tickers

ALKS


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

9-analysts-assess-alkermes-what-you-need-to-know
9 Analysts Assess Alkermes: What You Need ...
09/26/2025 13:00:29

Analysts' ratings for Alkermes (NASDAQ: ALKS) over the last quarter vary from bullish to bearish, as provided by 9 analysts...

this-ciena-analyst-turns-bullish-here-are-top-5-upgrades-for-friday
This Ciena Analyst Turns Bullish; Here Are...
09/26/2025 11:55:03

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

rbc-capital-upgrades-alkermes-to-outperform-raises-price-target-to-44
RBC Capital Upgrades Alkermes to Outperfor...
09/26/2025 11:40:04

RBC Capital analyst Leonid Timashev upgrades Alkermes (NASDAQ: ALKS) from Sector Perform to Outperform and raises the price ...

alkermes-appoints-joshua-reed-as-cfo-effective-september-15-2025
Alkermes Appoints Joshua Reed As CFO, Effe...
09/12/2025 13:01:24

jp-morgan-maintains-neutral-on-alkermes-raises-price-target-to-35
JP Morgan Maintains Neutral on Alkermes, R...
09/09/2025 19:43:27

JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the price target from $34 to $35.

hc-wainwright--co-reiterates-neutral-on-alkermes-maintains-46-price-target
HC Wainwright & Co. Reiterates Neutral on ...
09/09/2025 10:48:19

HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $46 price target.

alkermes-vibrance-1-study-demonstrates-alixorexton-significantly-reduces-cataplexy-rates-with-more-than-40-of-patients-achieving-complete-reduction
Alkermes Vibrance 1 Study Demonstrates Ali...
09/08/2025 07:18:30

– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cog...

deep-dive-into-alkermes-stock-analyst-perspectives-7-ratings
Deep Dive Into Alkermes Stock: Analyst Per...
09/03/2025 20:00:35

macys-increases-fy2025-outlook-joins-rev-group-healthequity-alphabet-and-wellness-and-other-big-stocks-moving-higher-on-wednesday
Macy's Increases FY2025 Outlook, Joins REV...
09/03/2025 14:10:50

this-unisys-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday
This Unisys Analyst Begins Coverage On A B...
09/03/2025 12:40:11

wells-fargo-initiates-coverage-on-alkermes-with-overweight-rating-announces-price-target-of-44
Wells Fargo Initiates Coverage On Alkermes...
09/03/2025 12:35:48

Wells Fargo analyst Benjamin Burnett initiates coverage on Alkermes (NASDAQ:ALKS) with a Overweight rating and announces Pri...

bruker-mineralys-therapeutics-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Bruker, Mineralys Therapeutics And Other B...
09/03/2025 12:17:14

alkermes-to-present-detailed-results-from-its-vibrance-1-phase-2-study-evaluating-alixorexton-in-patients-with-narcolepsy-type-1-at-world-sleep-congress
Alkermes To Present Detailed Results From ...
08/25/2025 11:07:52

Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures,...

rbc-capital-maintains-sector-perform-on-alkermes-raises-price-target-to-42
RBC Capital Maintains Sector Perform on Al...
07/30/2025 13:56:51

RBC Capital analyst Leonid Timashev maintains Alkermes (NASDAQ:ALKS) with a Sector Perform and raises the price target from ...

needham-reiterates-buy-on-alkermes-maintains-45-price-target
Needham Reiterates Buy on Alkermes, Mainta...
07/29/2025 12:03:26

Needham analyst Ami Fadia reiterates Alkermes (NASDAQ:ALKS) with a Buy and maintains $45 price target.

alkermes-affirms-fy2025-gaap-eps-guidance-of-103-121-vs-115-est-affirms-fy2025-sales-guidance-of-1340b-1430b-vs-1385b-est
Alkermes Affirms FY2025 GAAP EPS Guidance ...
07/29/2025 11:06:29

Alkermes (NASDAQ:ALKS) affirms FY2025 GAAP EPS guidance from $1.03-$1.21 to $1.03-$1.21 vs $1.15 analyst estimate. Affirms FY20...

alkermes-q2-eps-052-beats-024-estimate-sales-390657m-beat-342116m-estimate
Alkermes Q2 EPS $0.52 Beats $0.24 Estimate...
07/29/2025 11:03:58

Alkermes (NASDAQ:ALKS) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.24 by 117...

Core News & Articles
Earnings Scheduled For July 29, 2025
07/29/2025 08:32:31

alkermes-oral-drug-helps-patients-stay-awake-in-mid-stage-sleep-disorder-study
Alkermes Oral Drug Helps Patients Stay Awa...
07/21/2025 17:29:02

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...

hc-wainwright--co-reiterates-neutral-on-alkermes-maintains-46-price-target
HC Wainwright & Co. Reiterates Neutral on ...
07/21/2025 16:11:29

HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $46 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION